Clinical trial
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
NCT00159679 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00159679 |
|---|---|
| Title | Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy |
| Official title | A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetic Neuropathy, Painful |
| Intervention type | Drug |
| Interventions | Pregabalin |
| Enrollment | 167 |
| Start date | Sep 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 25, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: